Imagine battling a relentless disease like oral cancer, only to be further tormented by excruciating pain and debilitating side effects from treatment. It's a grim reality for many, but hope is on the horizon! Researchers are making groundbreaking strides thanks to a significant boost in funding from the National Institutes of Health (NIH).
The School of Dentistry at UT Health San Antonio has secured three multi-year grants, totaling a staggering $6 million, to tackle the multifaceted challenges of oral cancer. This isn't just about fighting the cancer itself; it's about alleviating the suffering it inflicts.
These grants will fuel research into:
- Novel targets for oral squamous cell carcinoma: This is the most common type of oral cancer, and unfortunately, it's often diagnosed at a late stage. The goal is to find new ways to stop this aggressive cancer in its tracks.
- Innovative treatments for oral mucositis: Radiotherapy, a common cancer treatment, often causes severe inflammation and ulcers in the mouth – a condition known as oral mucositis. This research aims to develop gentler and more effective ways to manage this painful side effect.
- Understanding and reducing oral cancer pain: Pain is a constant companion for many oral cancer patients. This grant will explore new mechanisms behind this pain, paving the way for the development of better pain management strategies. And this is the part most people miss: It's not just about masking the pain, but about treating the underlying cause.
"Taken together, these grants represent new promise in addressing both the treatment and conditions of oral cancer that, unfortunately, is growing more common and carries relatively low survival rates. In so doing, this research could lead to the development of new and transformative therapies," says Kenneth Hargreaves, DDS, PhD, professor and dean of the School of Dentistry, and director of its Center for Pain Therapeutics and Addiction Research.
Tackling a Deadly Cancer Head-On
Oral squamous cell carcinoma, which originates in the lining of the mouth, accounts for a staggering 95% of all oral cancer cases. What's even more alarming is its rising incidence and the fact that a significant number of patients are diagnosed when the disease is already advanced, leading to a disheartening five-year survival rate of just 38%. This type of cancer is a major contributor to head and neck cancers, claiming approximately 11,000 lives annually in the United States alone, with around 200,000 individuals currently living with this disease.
Dr. Cara Gonzales, DDS, PhD, Associate Professor of Comprehensive Dentistry at the School of Dentistry, has been awarded a two-year grant of $315,000 to investigate the potential of targeting TRPC1 (Transient Receptor Potential Canonical 1). TRPC1 is an ion channel that regulates the flow of sodium and calcium ions into cells. Dr. Gonzales's research will utilize both xenograft and syngeneic mouse models of oral squamous cell carcinoma. A xenograft model involves transplanting human cancer cells into immunodeficient mice, whereas a syngeneic model employs immunocompetent mice with tumors derived from genetically identical mice. These models will help determine the efficacy and toxicity of TRPC1 "knock-out" (inactivation) and pharmacological inhibition (using drugs to block TRPC1's function).
"Our overarching hypothesis is that TRPC1 inhibition will selectively kill oral cancer cells while leaving immune cell populations unharmed," Gonzales explained. Her project, "Targeting TRPC1: A Novel Approach to Treat Oral Cancer," was awarded in August. But here's where it gets controversial... some researchers believe that completely inhibiting TRPC1 could have unintended consequences on other cellular processes. What are your thoughts?
Easing the Agony of Mucositis
Radiation-induced oral mucositis (RIOM) is a common and agonizing side effect of radiotherapy in head and neck cancer patients. The painful inflammation and ulcers that characterize RIOM significantly impair a patient's quality of life and can even disrupt their cancer treatment. Despite its prevalence, the underlying mechanisms of RIOM are not fully understood, hindering the development of effective therapies.
Drs. Shivani Ruparel, PhD, Professor of Endodontics and Deputy Director of the Center for Pain Therapeutics and Addiction Research, and Brij B. Singh, PhD, Associate Dean for Research, have received a five-year, $3.1 million grant to explore a novel mechanism involving calcium, TRPM2, and inflammasome signaling in the development of oral mucositis. TRPM2 (Transient Receptor Potential Melastatin 2) is an ion channel that allows calcium to pass through and is involved in oxidative stress and inflammation, both key factors in RIOM. Inflammasome signaling is a cellular process that triggers an inflammatory response.
"Our goal is to investigate the role of TRPM2 in the development of RIOM and evaluate the potential of TRPM2 inhibition as a preventive treatment," Singh said. Their project, "TRPM2-Mediated Immune Activation Initiates Radiation-Induced Loss of Oral Function," was awarded in June. "We believe this will provide important new insights into new, effective treatment strategies."
Conquering Oral Cancer Pain
Pain management is a critical issue for oral cancer patients. However, the mechanisms behind this pain are poorly understood, which has hampered the development of new pain-relieving drugs.
Dr. Ruparel will lead a four-year, $2.6 million project to study the role of truncated TrkBT1 isoform, an alternative form of the Tyrosine Kinase B receptor, in mediating pain at the tumor site. TrkBT1 has been linked to neuropathic pain and injury.
"Given that TrkBT1 is the predominant isoform highly expressed in oral cancers, targeting this receptor signaling can prove to be an effective therapy for cancer-induced pain as well as tumor progression," Ruparel stated.
She emphasized that existing pain medications, particularly opiates, often provide limited relief or lead to rapid tolerance in oral cancer patients.
"This study's relevance lies in its potential to uncover novel therapeutic targets for managing oral cancer-induced pain and improving patients' quality of life," Ruparel explained. "By investigating the role of TrkBT1 in both sensory neurons and the tumor microenvironment, the research may pave the way for innovative treatments that address pain and oral tumorigenesis simultaneously."
The project, "Contribution of Truncated TrkB Isoform in Oral Cancer Pain," was awarded in August.
These three grants are aligned with the dental school's Center for Regenerative Sciences (Gonzales) and the Center for Pain Therapeutics and Addiction Research (Ruparel), as well as both centers jointly (Ruparel/Singh).
This research offers a beacon of hope for those affected by oral cancer. What do you think are the most promising avenues for future research in this field? Share your thoughts and let's discuss!
